The influence of hemodialysis on FibroTest parameters

1. Poux JM, Cadranel JF, Fievet P, Dumouchel P, Collot G. Measurement of gamma glutamyl transpeptidase activity: A useful and low-cost tool for the detection of HCV infection in haemodialysed patients. Nephrol Dial Transplant. 1998;13(5):1324. DOI: 10.1093/oxfordjournals.ndt.a02788610.1093/oxfordjournals.ndt.a027886Open DOISearch in Google Scholar

2. Pereira BJ, Levery AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997;51(4):981-999. DOI: 10.1038/ki.1997.13910.1038/ki.1997.1399083262Open DOISearch in Google Scholar

3. Weber D, Rutala W, Fried M. Hepatitis C Virus Outbreaks in Hemodialysis Centers: A Continuing Problem. Infection Control & Hospital Epidemiology. 2016;37(2):140-142. DOI: 10.1017/ice.2015.31110.1017/ice.2015.31126813313Open DOISearch in Google Scholar

4. Grigorescu M. HCV genotype 1 is almost exclusively present in Romanian patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2009;18(1):45-50.Search in Google Scholar

5. Nițescu M, Vâjâitu C, Săndulescu O, Streinu-Cercel A, Pițigoi D, Preoțescu LL, et al. Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals. Rev Romana Med Lab. 2017;25(4):355-63. DOI: 10.1515/rrlm-2017-003010.1515/rrlm-2017-0030Open DOISearch in Google Scholar

6. Chen QW, Cheng CS, Chen H, Ning ZY, Tang SF, Zhang X, et al. Effectiveness and complications of ultrasound guided fine needle aspiration for primary liver cancer in a Chinese population with serum α-fetoprotein levels ≤200 ng/ml - A study based on 4,312 patients. PLoS One. 2014;9(8) :e101536. DOI: 10.1371/journal.pone.010153610.1371/journal.pone.0101536414935025170868Search in Google Scholar

7. Dzekova-Vidimliski P, Dzikova S, Selim G, Gelev S, Trajceska L, Pushevski V, Sikole A. Ultrasound predictors of compensated liver cirrhosis in hemodialysis patients with hepatitis C. Saudi J Kidney Dis Transpl. 2013;24(1):30-35. DOI: 10.4103/1319-2442.10623510.4103/1319-2442.10623523354188Open DOISearch in Google Scholar

8. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraob-server variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614-2618. DOI: 10.1111/j.1572-0241.2002.06038.x10.1111/j.1572-0241.2002.06038.x12385448Search in Google Scholar

9. Orasan OH, Orasan RA, Patiu IM, Dumitrascu DL. Hyaluronic acid in end-stage renal disease treated by hemodialysis. Ren Fail. 2015;37(9):1531-1532. DOI: 10.3109/0886022X.2015.107731210.3109/0886022X.2015.107731226337537Open DOISearch in Google Scholar

10. Orasan OH, Urian L, Ciulei G, et al. Thrombocytopenia in end-stage renal disease and chronic viral hepatitis B or C. J Mind Med Sci. 2018;5(2):236-243. DOI: 10.22543/7674.52.P23624310.22543/7674.52.P236243Search in Google Scholar

11. Jiang Y, Huang E, Mehrnia A, Kamgar M, Pham PT, Ogunorunyinka O, et al. Can aminotransferase-to-platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients? Nephrol Dial Transplant. 2014;29(6):1247-1252. DOI: 10.1093/ndt/gft48510.1093/ndt/gft48524353319Open DOISearch in Google Scholar

12. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. 2006;44(3):462-474. DOI: 10.1016/j.jhep.2005.10.01910.1016/j.jhep.2005.10.019Open DOISearch in Google Scholar

13. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-847. DOI: 10.1016/j.jhep.2008.02.00810.1016/j.jhep.2008.02.008Open DOISearch in Google Scholar

14. Liu CH, Liang CC, Huang KW, Liu CJ, Chen SI, Lin JW, et al. Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C Patients. Clin J Am Soc Nephrol. 2011;6(5):1057-1065. DOI: 10.2215/CJN.0432051010.2215/CJN.04320510Open DOISearch in Google Scholar

15. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation. 2005;80(11):1550-1555. DOI: 10.1097/01.tp.0000183399.85804.0210.1097/01.tp.0000183399.85804.02Open DOISearch in Google Scholar

16. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2011;357(9262):1069-1075. DOI: 10.1016/S0140-6736(00)04258-610.1016/S0140-6736(00)04258-6Open DOISearch in Google Scholar

17. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343-350. DOI: 10.1053/j.gastro.2004.11.01810.1053/j.gastro.2004.11.01815685546Open DOISearch in Google Scholar

18. Mikolasevic I, Orlic L, Zaputovic L, Racki S, Cubranic Z, Anic K, et al. Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. Wien Klin Wochenschr. 2015;127(11-12):451-458. DOI: 10.1007/s00508-015-0757-z10.1007/s00508-015-0757-z25854911Open DOISearch in Google Scholar

19. Canbakan M, Senturk H, Canbakan B, et al. Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C. Nephron Clin Pract. 2011;117(3):289-296. DOI: 10.1159/00032075110.1159/00032075120847572Open DOISearch in Google Scholar

20. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS-medicine. 2009;6(7):e1000097. DOI: 10.1371/journal.pmed.100009710.1371/journal.pmed.1000097270759919621072Search in Google Scholar

21. Moradi H, Said HM, Vaziri ND. Post-transcriptional nature of uremia-induced downregulation of he-patic apolipoprotein A-I production. Transl Res. 2013;161(6):477-485. DOI: 10.1016/j.trsl.2012.11.00110.1016/j.trsl.2012.11.001360994123219399Open DOISearch in Google Scholar

22. Pruijm M, Schmidtko J, Aho A, Pagano S, Roux-Lombard P, Teta D, et al. High Prevalence of Anti-Apolipoprotein/A-1 Autoantibodies in Maintenance Hemo-dialysis and Association With Dialysis Vintage. Ther Apher Dial. 2012;16(6):588-594. DOI: 10.1111/j.1744-9987.2012.01102.x10.1111/j.1744-9987.2012.01102.x23190520Open DOISearch in Google Scholar

23. Rolla R, De Mauri A, Valsesia A, Vidali M, Chiarinotti D, Bellomo G. Lipoprotein profile, lipoprotein-associated phospholipase A2 and cardiovascular risk in hemodialysis patients. J Nephrol. 2015;28(6):749-755. DOI: 10.1007/s40620-015-0194-010.1007/s40620-015-0194-025971848Open DOISearch in Google Scholar

24. Calabresi L, Simonelli S, Conca P, et al. Acquired leci-thin: Cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med. 2015;277(5):552-561. DOI: 10.1111/joim.1229010.1111/joim.1229025039266Open DOISearch in Google Scholar

25. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res. 2009;153(2):77-85. DOI: 10.1016/j.trsl.2008.11.00710.1016/j.trsl.2008.11.00719138652Open DOISearch in Google Scholar

26. Pahl MV, Ni Z, Sepassi L, Moradi H, Vaziri ND. Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD). Nephrol Dial Transplant. 2009;24(8):2541-2546. DOI: 10.1093/ndt/gfp12010.1093/ndt/gfp120272729919297356Search in Google Scholar

27. Kaysen GA, Dalrymple LS, Grimes B, Chertow GM, Kornak J, Johansen KL. Changes in serum inflammatory markers are associated with changes in apolipoprotein A1 but not B after the initiation of dialysis. Nephrol Dial Transplant. 2014;29(2):430-437. DOI: 10.1093/ndt/gft37010.1093/ndt/gft370391033924009290Open DOISearch in Google Scholar

28. Honda H, Hirano T, Ueda M, Kojima S, Mashiba S, Hayase Y, et al. High-Density Lipoprotein Subfractions and Their Oxidized Subfraction Particles in Patients with Chronic Kidney Disease. J Atheroscler Thromb. 2016;23(1):81-94. DOI: 10.5551/jat.3001510.5551/jat.3001526289085Open DOISearch in Google Scholar

29. Ribeiro S, do Sameiro Faria M, Mascarenhas-Melo F, Freitas I, Mendonça MI, Nascimento H, et al. Main determinants of PON1 activity in hemodialysis patients. Am J Nephrol. 2012;36(4):317-323. DOI: 10.1159/00034223510.1159/00034223523007074Open DOISearch in Google Scholar

30. Kimak E, Hałabiś M, Baranowicz-Gąszczyk I, Solski J, Książek A. Association between moderately oxidized low-density lipoprotein and high-density lipo-protein particle subclass distribution in hemodialyzed and post-renal transplant patients. J Zhejiang Univ Sci B.2011;12(5):365-371. DOI: 10.1631/jzus.B100034810.1631/jzus.B1000348308709221528490Open DOISearch in Google Scholar

31. Lokesh S, Kadavanu TM,Green SR, et al. A Comparative Study of Lipid Profile and Cardiovascular Risk Biomarkers Among Chronic Haemodialysis Patients and Healthy Individuals. J Clin Diagnostic Res. 2016;10(9):36-40. DOI: 10.7860/JCDR/2016/21897.852310.7860/JCDR/2016/21897.8523507198627790486Open DOISearch in Google Scholar

32. Ikewaki K. In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease. Clin Exp Nephrol. 2014;18(2):261-264. DOI: 10.1007/s10157-013-0881-x10.1007/s10157-013-0881-x24129559Open DOISearch in Google Scholar

33. Yeo Y, Byun SW, Lee JY, Min WK, Park JS, Kim SB. Lack of association between small dense low-density lipoprotein levels and coronary artery disease in chronic hemodialysis patients. Am J Nephrol. 2009;30(3):310-314. DOI: 10.1159/00022593910.1159/00022593919546529Open DOISearch in Google Scholar

34. Samouilidou EC, Grapsa E. Relationship of serum cystatin C with C-reactive protein and apolipoprotein A1 in patients on hemodialysis. Ren Fail. 2008;30(7):711-715. DOI: 10.1080/0886022080221297310.1080/0886022080221297318704820Open DOISearch in Google Scholar

35. Wu S, Chen X, Yuan S, Peng D, Zhou A, Li J. Impaired cholesterol efflux capacity is related to increased carotid intima media thickness in patients with end-stage renal disease. Int J Cardiol. 2015;187(1):456-458. DOI: 10.1016/j.ijcard.2015.03.36210.1016/j.ijcard.2015.03.36225841149Open DOISearch in Google Scholar

36. Moradi H, Said HM, Vaziri ND. Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production. Transl Res. 2013;161(6):477-485. DOI: 10.1016/j.trsl.2012.11.00110.1016/j.trsl.2012.11.001360994123219399Open DOISearch in Google Scholar

37. Holzer M, Birner-Gruenberger R, Stojakovic T, et al. Uremia Alters HDL Composition and Function. J Am Soc Nephrol. 2011;22(9):1631-1641. DOI: 10.1681/ASN.201011114410.1681/ASN.2010111144317193521804091Open DOISearch in Google Scholar

38. Boon AC, Bulmer AC, Coombes JS, Fassett RG. Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations. AJP Ren Physiol. 2014;307(2):F123-136. DOI: 10.1152/ajprenal.00039.201410.1152/ajprenal.00039.201424761005Open DOISearch in Google Scholar

39. Mekki K, Taleb W, Bouzidi N, Kaddous A, Bouchenak M. Effect of hemodialysis and peritoneal dialysis on redox status in chronic renal failure patients: a comparative study. Lipids Health Dis. 2010;9:93. DOI: 10.1186/1476-511X-9-9310.1186/1476-511X-9-93294148920815897Open DOISearch in Google Scholar

40. Si X, Li J, Bi X, Wu L, Wu X. Clinical evaluation of high-volume hemofiltration with hemoperfusion followed by intermittent hemodialysis in the treatment of acute wasp stings complicated by multiple organ dys-function syndrome. PLoS One. 2015;10(7):1-11. DOI: 10.1371/journal.pone.013270810.1371/journal.pone.0132708451485826207371Open DOISearch in Google Scholar

41. Tbahriti HF, Kaddous A, Bouchenak M, Mekki K. Effect of Different Stages of Chronic Kidney Disease and Renal Replacement Therapies on Oxidant-Anti-oxidant Balance in Uremic Patients. Biochem Res Int. 2013;2013:1-6. DOI: 10.1155/2013/35898510.1155/2013/358985387669124416590Open DOISearch in Google Scholar

42. Zhang L, Yang Y, Tang Y, Zhao Y, Cao Y, Su B, et al. Recovery from AKI following multiple wasp stings: A case series. Clin J Am Soc Nephrol. 2013;8(11):1850-1856. DOI: 10.2215/CJN.1208111210.2215/CJN.12081112Open DOISearch in Google Scholar

43. Cheng YC, Kuo WW, Wu CH, Shu WT, Kuo CH, Hwang JM, et al. Iron status and cardiovascular risk factors in patients with haemodialysis versus patients with ischaemic heart disease. Nephrol. 2009;14(1):65-69. DOI: 10.1111/j.1440-1797.2008.01004.x10.1111/j.1440-1797.2008.01004.xOpen DOISearch in Google Scholar

44. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat. 2002;9(2):128-133. DOI: 10.1046/j.1365-2893.2002.00341.x10.1046/j.1365-2893.2002.00341.xOpen DOISearch in Google Scholar

45. Bacq Y, Schillio Y, Brechot JF, De Muret A, Dubois F, Metman EH. Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol. 1993;17(5):364-369.Search in Google Scholar

46. Trznadel K, Luciak M, Paradowski M, Kubasiewicz-Ujma B. Hemodialysis and the acute-phase response in chronic uremic patients. Int J Artif Organs. 1989;12(12):762-765. DOI: 10.1177/03913988890120120510.1177/039139888901201205Open DOISearch in Google Scholar

47. Argilés A, Kerr PG, Mourad G, Mion CM, Atkins RC. Serum alpha 2-macroglobulin in haemodialysis patients: baseline and kinetic studies. Nephrol Dial Transpl. 1993;8(10):1118-1123.Search in Google Scholar

48. Petrauskiene V, Vaiciuniene R, Kuzminskis V, Ziginskiene E, Grazulis S, Jonaitiene E, et al. Associations of vascular calcification, calcium phosphate disturbances, FGF 23 and Matrix Gla protein with mortality of hemodialysis patients: one center cohort study. Rev Romana Med Lab. 2018;26(4):451-60. DOI:10.2478/rrlm-2018-0034. DOI: 10.2478/rrlm-2018-003410.2478/rrlm-2018-0034.DOI:10.2478/rrlm-2018-0034Open DOISearch in Google Scholar

49. Maor Y, Calès P, Bashari D, et al. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia. 2007;13(6):722-729. DOI: 10.1111/j.1365-2516.2007.01548.x10.1111/j.1365-2516.2007.01548.xOpen DOISearch in Google Scholar

50. Lin YP, Yang CY, Liao CC, Yu WC, Chi CW, Lin CH. Plasma protein characteristics of long-term hemodialysis survivors. PLoS One. 2012;7(7):e40232. DOI: 10.1371/journal.pone.004023210.1371/journal.pone.0040232Search in Google Scholar

51. Fabrizi F, de Vecchi AF, Qureshi AR, et al. Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population. Int J Artif Organs. 2007;30(1):6-15. DOI: 10.1177/03913988070300010310.1177/039139880703000103Open DOISearch in Google Scholar

52. Souza JF, Longui CA, Miorin LA, Sens YA. Gamma-Glutamyltransferase Activity in Chronic Dialysis Patients and Renal Transplant Recipients With Hepatitis C Virus Infection. Transplant Proc. 2008;40(5):1319-1323. DOI: 10.1016/j.transproceed.2008.03.15710.1016/j.transproceed.2008.03.157Open DOISearch in Google Scholar

53. Liberato I, Lopes E, Cavalcante M, Pinto T, Moura I, Loureiro-Jr L. Liver enzymes in patients with chronic kidney disease undergoing peritoneal dialysis and hemodialysis. Clinics. 2012;67(2):131-134. DOI: 10.6061/clinics/2012(02)0710.6061/clinics/2012(02)07Open DOISearch in Google Scholar